Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
27.69
-0.34 (-1.21%)
Streaming Delayed Price
Updated: 3:33 PM EDT, Mar 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
May 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
May 22, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
May 16, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
Travere Therapeutics's Earnings: A Preview
↗
April 30, 2025
Via
Benzinga
Analyst Expectations For Travere Therapeutics's Future
↗
February 24, 2025
Via
Benzinga
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
↗
May 16, 2025
Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug.
Via
Investor's Business Daily
Topics
Government
Top movers in Friday's pre-market session
↗
May 16, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 16, 2025
Via
Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
↗
May 16, 2025
Via
Benzinga
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries
↗
May 16, 2025
Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026.
Via
Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
May 15, 2025
Via
Benzinga
Thursday's after hours session: top gainers and losers
↗
May 15, 2025
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
May 15, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 07, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
↗
May 02, 2025
Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX).
Via
Chartmill
Travere Therapeutics Reports First Quarter 2025 Financial Results
May 01, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
April 29, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics to Report First Quarter 2025 Financial Results
April 24, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
↗
April 23, 2025
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
↗
April 03, 2025
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.
Via
Investor's Business Daily
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts
↗
April 01, 2025
Via
Benzinga
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
April 01, 2025
Via
Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
March 31, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
March 17, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Participate at Upcoming Investor Conferences
February 24, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
